Promoter methylation of BRCA1 in triple-negative breast cancer predicts sensitivity to adjuvant chemotherapy

Annals of Oncology

Volumn 24, Issue 6, 2013, Pages 1498-1505

  Xu, Y ^a   Diao, L ^a   Chen, Y ^a   Liu, Y ^a   Wang, C ^a   Ouyang, T ^a   Li, J ^a   Wang, T ^a   Fan, Z ^a   Fan, T ^a   Lin, B ^a   Deng, D ^a   Narod, S A ^b   Xie, Y ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

BRCA1 methylation; Chemotherapy; Triple negative breast cancer

Indexed keywords

ANTHRACYCLINE; BRCA1 PROTEIN; CYCLOPHOSPHAMIDE; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PACLITAXEL; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISEASE SPECIFIC SURVIVAL; DNA METHYLATION; DRUG SENSITIVITY; FEMALE; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PARTIAL MASTECTOMY; PREDICTION; PRIORITY JOURNAL; PROMOTER REGION; SURVIVAL TIME; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST CANCER; TUMOR SUPPRESSOR GENE;

EID: 84878444306     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt011     Document Type: Article

References (41)

1. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med 2010; 363: 1938-1948.
2. Reis-Filho JS, Tutt AN. Triple negative tumours: a critical review. Histopathology 2008; 52: 108-118.
3. Haffty BG, Yang Q, Reiss M et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 2006; 24: 5652-5657.
4. Rakha EA, El-Sayed ME, Green AR et al. Prognostic markers in triple-negative breast cancer. Cancer 2007; 109: 25-32.
5. Liedtke C, Mazouni C, Hess KR et al. Response to neoadjuvant therapy and longterm survival in patients with triple-negative breast cancer. J Clin Oncol 2008; 26: 1275-1281.
6. Carey LA, Dees EC, Sawyer L et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007; 13: 2329-2334.
7. Hudis CA, Gianni L. Triple-negative breast cancer: an unmet medical need. Oncologist 2011; 16(Suppl 1): 1-11.
8. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a populationbased series of breast cancer cases. Anglian Breast Cancer Study Group. Br J Cancer 2000; 83: 1301-1308.
9. Ponder BA. Cancer genetics. Nature 2001; 411: 336-341.
10. Fackenthal JD, Olopade OI. Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. Nat Rev Cancer 2007; 7: 937-948.
11. Suter NM, Ray RM, Hu YW et al. BRCA1 and BRCA2 mutations in women from Shanghai China. Cancer Epidemiol Biomarkers Prev 2004; 13: 181-189.
12. Rice JC, Ozcelik H, Maxeiner P et al. Methylation of the BRCA1 promoter is associated with decreased BRCA1 mRNA levels in clinical breast cancer specimens. Carcinogenesis 2000; 21: 1761-1765.
13. Esteller M, Silva JM, Dominguez G et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 2000; 92: 564-569.
14. Jeronimo C, Costa I, Martins MC et al. Detection of gene promoter hypermethylation in fine needle washings from breast lesions. Clin Cancer Res 2003; 9: 3413-3417.
15. Xu X, Gammon MD, Zhang Y et al. BRCA1 promoter methylation is associated with increased mortality among women with breast cancer. Breast Cancer Res Treat 2009; 115: 397-404.
16. Chen Y, Zhou J, Xu Y et al. BRCA1 promoter methylation associated with poor survival in Chinese patients with sporadic breast cancer. Cancer Sci 2009; 100: 1663-1667.
17. Eads CA, Laird PW. Combined bisulfite restriction analysis (COBRA). Methods Mol Biol 2002; 200: 71-85.
18. Herman JG, Graff JR, Myohanen S et al. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996; 93: 9821-9826.
19. Thorpe SM. Steroid receptors in breast cancer: sources of inter-laboratory variation in dextran-charcoal assays. Breast Cancer Res Treat 1987; 9: 175-189.
20. Shi L, Dong B, Li Z et al. Expression of ER-{alpha}36, a novel variant of estrogen receptor {alpha}, and resistance to tamoxifen treatment in breast cancer. J Clin Oncol 2009; 27: 3423-3429.
21. Silver DP, Richardson AL, Eklund AC et al. Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J Clin Oncol 2010; 28: 1145-1153.
22. Lips EH, Mulder L, Hannemann J et al. Indicators of homologous recombination deficiency in breast cancer and association with response to neoadjuvant chemotherapy. Ann Oncol 2011; 22: 870-876.
23. Turner N, Tutt A, Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev 2004; 4: 1-6.
24. Scully R, Ganesan S, Vlasakova K et al. Genetic analysis of BRCA1 function in a defined tumor cell line. Mol Cell 1999; 4: 1093-1099.
25. Kennedy RD, Quinn JE, Mullan PB et al. The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst 2004; 96: 1659-1668.
26. Tassone P, Tagliaferri P, Perricelli A et al. BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br J Cancer 2003; 88: 1285-1291.
27. Byrski T, Gronwald J, Huzarski T et al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 2010; 28: 375-379.
28. Arun B, Bayraktar S, Liu DD et al. Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience. J Clin Oncol 2011; 29: 3739-3746.
29. Hedenfalk I, Duggan D, Chen Y et al. Gene-expression profiles in hereditary breast cancer. N Engl J Med 2001; 344: 539-548.
30. Dent R, Trudeau M, Pritchard KI et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007; 13: 4429-4434.
31. Feki A, Irminger-Finger I. Mutational spectrum of p53 mutations in primary breast and ovarian tumors. Crit Rev Oncol Hematol 2004; 52: 103-116.
32. Carey LA, Perou CM, Livasy CA et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. Jama 2006; 295: 2492-2502.
33. Greenblatt MS, Chappuis PO, Bond JP et al. TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: distinctive spectrum and structural distribution. Cancer Res 2001; 61: 4092-4097.
34. Vincent-Salomon A, Ganem-Elbaz C, Manie E et al. X inactive-specific transcript RNA coating and genetic instability of the X chromosome in BRCA1 breast tumors. Cancer Res 2007; 67: 5134-5140.
35. Carey LA. Directed therapy of subtypes of triple-negative breast cancer. Oncologist 2010; 15(Suppl 5): 49-56.
36. Fong PC, Boss DS, Yap TA et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361: 123-134.
37. Tutt A, Robson M, Garber JE et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010; 376: 235-244.
38. O'Shaughnessy J, Osborne C, Pippen JE et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 2011; 364: 205-214.
39. O'Shaughnessy J, Schwartzberg LS, Danso MA et al. A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). J Clin Oncol, 2011 ASCO Annu Meeting Proc 2011; 29: 1007.
40. Drew Y, Mulligan EA, Vong WT et al. Therapeutic potential of poly(ADPribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2. J Natl Cancer Inst 2011; 103: 334-346.
41. Veeck J, Ropero S, Setien F et al. BRCA1 CpG island hypermethylation predicts sensitivity to poly(adenosine diphosphate)-ribose polymerase inhibitors. J Clin Oncol 2010; 28: e563-564. author reply e565-566.